Health Condition 1: E119- Type 2 diabetes mellitus without complications
Conditions
Interventions
Intervention1: Ptyrone: 2 Capsules (425 mg/Capsule)orally for two times in a day for 12 weeks
Control Intervention1: NA: NA
Sponsors
SSV Phytopharmaceuticals
Eligibility
Inclusion criteria
Inclusion criteria: 1.Male and female aged 18 to 65 who are suffering from type 2 diabetes mellitus. 2.Willing to give informed consent.
Exclusion criteria
Exclusion criteria: 1.Patients who are suffering from any other systemic illness other than type 2 diabetes mellitus or megaloblastic anaemia. 2.Patients who are on corticosteroids and oral contraceptives 3.Patients with seropositive status. 4.Pregnancy 5.Patients Participation in clinical trials evaluating investigational pharmaceuticals or biologics within 3 months or devices within 30 days of admission to the study. 6.History of alcohol. substance abuse or alcoholism, within the previous one year
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary objective of the study is to evaluate the activity and tolerability of Ptyrone in patients with treated uncontrolled type 2 diabetes mellitus.Timepoint: 12 weeks | — |
Secondary
| Measure | Time frame |
|---|---|
| Safety and tolerability; clinical and metabolic variables.Timepoint: 12 weeks | — |
Countries
India
Contacts
Public ContactYogesh Dound
Kokan Hospital
Outcome results
None listed